Literature DB >> 3312809

Hyperplastic polyps of the colon and rectum. An immunohistochemical study with monoclonal antibodies against blood groups antigens (sialosyl-Lea, Leb, Lex, Ley, A, B, H).

H S Cooper1, C Marshall, F Ruggerio, Z Steplewski.   

Abstract

We studied 40 hyperplastic polyps (HP) immunohistochemically with monoclonal antibodies against 8 different blood group antigens (BGA) comparing their reactivity with normal control colon and colorectal adenocarcinomas. The 8 BGA studied were: Sialosyl-Lea, Lea, Leb, Lex, Ley, A,B, and H. sialosyl-Lea, Lea, Lex, and Ley can be though of as differentiation antigens. The former 2 BGA are expressed on mature (differentiated) epithelium while the latter 2 BGA are expressed by undifferentiated epithelium of the crypt base. A, B, H and Leb are not expressed in the normal distal colon, however, they are extensively expressed on distal colorectal cancers and adenomas and can be considered oncofetal BGA. HP expressed Lea, Lex, Ley in the same compartment of the crypt as normal colon and extensively expressed Sialosyl-Lea throughout the entire length of the crypt. This latter finding indicated maturation at a lower point in the crypt than in normals. All HP failed to express B and H BGA, while 6 of 40 expressed Leb and 5 of 40 HP expressed A BGA. Of the 6 HP expressing Leb BGA, 3 were from patients with synchronous or metachronous cancers and 2 from patients with mixed hyperplastic polyp-adenomas (HP/AD). Two of the HP expressing A BGA were from patients with HP/AD. The expression and distribution of these BGA in HP, especially the extensive expression of sialosyl-Lea correlates with the known cell kinetics of HP. While nonneoplastic in nature, HP may occasionally express true oncofetal BGA. Similarly, the HP component of HP/AD may also express true oncofetal BGA. These data suggest that the lesions classified morphologically as HP may be antigenically heterogenous.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312809

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

1.  Blood group reactivities of SLCL-workshop antibodies.

Authors:  M Ernst; H H Sonneborn
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Colonic lipomas: our experience in diagnosis and treatment.

Authors:  I Mantzoros; D Raptis; M G Pramateftakis; D Kanellos; S Psomas; A Makrantonakis; T Tsachalis; S Angelopoulos
Journal:  Tech Coloproctol       Date:  2011-10       Impact factor: 3.781

3.  [Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens].

Authors:  A Larena; M Vierbuchen; S Schröder; A Larena-Avellaneda; I Hadshiew; R Fischer
Journal:  Langenbecks Arch Chir       Date:  1996

4.  Expression of blood group antigens H-2, Le(y), and sialylated-Le(a) in human colorectal carcinoma. An immunohistochemical study using double-labeling techniques.

Authors:  H S Cooper; M J Malecha; C Bass; P L Fagel; Z Steplewski
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

5.  Comparative study on the expression of the blood group antigens Le a, Le b, Le x, Le y and the carbohydrate antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.

Authors:  J Schwenk; J Makovitzky
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

6.  An immunohistochemical study of the distribution of blood group substances and related antigens in primary colorectal carcinomas and metastatic lymph node and liver lesions, using monoclonal antibodies against A, B, H type 2, Le(a), and Le(x) antigens.

Authors:  T Nakagoe; K Fukushima; M Hirota; H Kusano; H Ayabe; M Tomita; S Kamihira
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

7.  Specific Norovirus Interaction with Lewis x and Lewis a on Human Intestinal Inflammatory Mucosa during Refractory Inflammatory Bowel Disease.

Authors:  Georges Tarris; Alexis de Rougemont; Marie Estienney; Maeva Charkaoui; Thomas Mouillot; Bernard Bonnotte; Christophe Michiels; Laurent Martin; Gaël Belliot
Journal:  mSphere       Date:  2021-01-13       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.